Group 1 - The core point of the announcement is that MicroPort Medical (00853) has entered into a merger agreement to acquire CRM Cayman, which will become a wholly-owned subsidiary of MicroPort CardioFlow upon the merger's effectiveness [1][2] - The acquisition price is set at HKD 1.35 per share for the shareholders of CRM Cayman, including its indirect wholly-owned subsidiary, MicroPort International Corp. Limited [1] - Following the merger, CRM Cayman and its subsidiaries will continue to operate as subsidiaries of MicroPort CardioFlow, enhancing the company's overall structure [1] Group 2 - The merger aligns with MicroPort CardioFlow's strategic development goals, aiming to establish a globally positioned cardiac product platform [2] - This strategic move is expected to diversify MicroPort CardioFlow's product offerings and pipelines, leading to complementary synergies [2] - The anticipated synergies will enhance MicroPort CardioFlow's capabilities in structural heart disease and cardiac rhythm disease solutions, including R&D, manufacturing, distribution channels, and market expansion [2]
微创医疗(00853)：微创心通拟合并CRM Cayman 打造心脏病综合解决方案平台